抑制PDK1的活性是抗癌藥物研發的目標之一。在本研究中，使用Autodock程式進行了ligand-PDK1複合體的docking計算，再現了目前已知的九個ligand-PDK1實驗結構。除了其中兩個ligand以外，其餘的錯合體結合能與實驗所得IC50值呈現相關性。為了設計更好的抑制劑，我們做了一些低IC50值的藥物UCN(nM)、BIM8(μM)，及其衍生物的docking計算。有幾個得到更大的結合能，代表其為更好的抑制劑，並討論穩定複合體之作用力。另外，也計算了一系列以Celebrex為基礎的化合物，其計算結果與實驗IC50的相關度也報告、討論於此論文中。

Inhibition of PDK1 kinase activity is one of the targets in developing cancer drug. In the present study, a docking calculation for ligand-PDK1 kinase complexes was carried out using the Autodock program. Experimental binding modes of 9 available lignad-PDK1 structures were reproduced. The binding energies of these complexes were correlated well with experimental IC50 values except 2 ligands. Toward designing better inhibitors, we have carried out docking calculation for a number of derivatives of the inhibitors of low IC50 value, UCN (in nM range) and BIM8. The calculations for several derivatives gave lower binding energy, suggesting that they are better inhibitors. The rationals of the calculated binding energies are discussed. In addition, calculations for a series of celebrex-based compounds were also carried out. Their correlations with experimental available IC50 values are discussed as well.

1. Clare, B. W.; Supuran, C. T. Carbonic anhydrase inhibitors. Part 86. A QSAR studyon some sulfonamide drugs which lower intra-ocular pressure,using the ACE non-linear statistical method. European Journal of Medicinal Chemistry 2000, 35, 859-865.
2. Hugo, K. Success Stories of Computer-Aided Design. In Computer Applications in Pharmaceutical Research and Development, Sean, E., Ed. 2006; pp 377-424.
3. von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
4. Charifson, P.; Kuntz, I. D. Recent Successes and Continuing Limitations in Computer-Aided Drug Design. In Practical Application of Computer-Aided Drug Design, Charifson, P., Ed. Marcel-Dekker: New York, 1997; pp 1-37.
5. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W. A review of protein-small molecule docking methods. Journal of Computer-Aided Molecular Design 2002, 16, 151-166.
6. Eccleston, A.; Dhand, R. Signalling in cancer. Nature 2006, 441, 423-423.
7. Shaw, R. J.; Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441, 424-430.
8. Scapin, G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discovery Today 2002, 7, 601-611.
9. Vivanco, I.; Sawyers, C. L. The Phosphatidylinositol 3-Kinase-AKT Pathway In Human Cancer. Nature Reviews Cancer 2002, 2, 489-501.
10. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
11. Christofori, G. New signals from the invasive front. Nature 2006, 441, 444-450.
12. Karin, M. Nuclear factor-[kappa]B in cancer development and progression. Nature 2006, 441, 431-436.
13. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
14. Westheimer, F. H. Why nature chose phosphates. Science 1987, 235, 1173-1178.
15. Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N. Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase and Sensitizes Tumors to Taxol. Cancer Res 2003, 63, 2139-2144.
16. Biondi, R. M.; Komander, D.; Thomas, C. C.; Lizcano, J. M.; Deak, M.; Alessi, D. R.; Aalten, D. M. F. v. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 2002, 21, 4219-4228.
17. Komander, D.; Kular, G. S.; Schüttelkopf, A. W.; Deak, M.; Prakash, K. R. C.; Bain, J.; Elliott, M.; Garrido-Franco, M.; Kozikowski, A. P.; Alessi, D. R.; Aalten, D. M. F. v. Interactions of LY333531 and Other Bisindolyl Maleimide Inhibitors with PDK1. Structure 2004, 12, 215-226.
18. Feldman, R. I.; Wu, J. M.; Polokoff, M. A.; Kochanny, M. J.; Dinter, H.; Zhu, D.; Biroc, S. L.; Alicke, B.; Bryant, J.; Yuan, S.; Buckman, B. O.; Lentz, D.; Ferrer, M.; Whitlow, M.; Adler, M.; Finster, S.; Chang, Z.; Arnaiz, D. O. Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1. J. Biol. Chem. 2005, 280, 19867-19874.
19. Komander, D.; Kular, G. S.; Bain, J.; Elliott, M.; Alessi, D. R.; Van Aalten, D. M. F. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003, 375, 255-262.
20. Hsu, A.-L.; Ching, T.-T.; Wang, D.-S.; Song, X.; Rangnekar, V. M.; Chen, C.-S. The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2. J. Biol. Chem. 2000, 275, 11397-11403.
21. Johnson, A. J.; song, X.; Hsu, A.-L.; Chen, C.-S. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Advances in Enzyme Regulation 2001, 41, 221-235.
22. Kulp, S. K.; Yang, Y.-T.; Hung, C.-C.; Chen, K.-F.; Lai, J.-P.; Tseng, P.-H.; Fowble, J. W.; Ward, P. J.; Chen, C.-S. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Res 2004, 64, 1444-1451.
23. Song, X.; Lin, H.-P.; Johnson, A. J.; Tseng, P.-H.; Yang, Y.-T.; Kulp, S. K.; Chen, C.-S. Cyclooxygenase-2, Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells. J. Natl. Cancer Inst. 2002, 94, 585-591.
24. Zhu, J.; Huang, J.-W.; Tseng, P.-H.; Yang, Y.-T.; Fowble, J.; Shiau, C.-W.; Shaw, Y.-J.; Kulp, S. K.; Chen, C.-S. From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Res 2004, 64, 4309-4318.
25. Moustakas, D.; Lang, P.; Pegg, S.; Pettersen, E.; Kuntz, I.; Brooijmans, N.; Rizzo, R. Development and validation of a modular, extensible docking program: DOCK 5. Journal of Computer-Aided Molecular Design 2006, 20, 601-619.
26. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 1998, 19, 1639-1662.
27. Ingo Schellhammer, M. R. FlexX-Scan: Fast, structure-based virtual screening. Proteins: Structure, Function, and Bioinformatics 2004, 57, 504-517.
28. Marcel L. Verdonk, J. C. C. M. J. H. C. W. M. R. D. T. Improved protein-ligand docking using GOLD. Proteins: Structure, Function, and Genetics 2003, 52, 609-623.
29. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47, 1739-1749.
30. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750-1759.
31. Morris, G. M.; Goodsell, D. S.; Huey, R.; Hart, W. E.; Halliday, S.; Belew, R.; Olson, A. J. AutoDock 3.0.5 User's Guide. The Scripps Research Institute: CA, 2001.
32. Holland, J. H. Adaptation in Natural and Artificial Systems. University of Michigan Press, Ann Arbor,: MI, 1975.
33. Yung-Chi, C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 1973, 22, 3099-3108.
34. Biondi, R. M.; Cheung, P. C. F.; Casamayor, A.; Deak, M.; Currie, R. A.; Alessi, D. R. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J. 2000, 19, 979-988.